ENOV ENOVIS CORPORATION

Enovis Debuts New Foot & Ankle Offerings at the AOFAS Annual Meeting

Enovis Debuts New Foot & Ankle Offerings at the AOFAS Annual Meeting

New solutions in Percutaneous and Open Bunion procedures, External Fixation, and Patient Specific Instrumentation, will be featured as part of the company’s growing evidence based, high tech portfolio.

Wilmington, DE, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Today, Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology company, announced it will showcase new products from its recent acquisitions of Novastep® and the external fixation assets of D.N.E., LLC, along with its new, organically developed Evolve34™ Lapidus Instrumentation, and the new “STAR+ Experience,” Enovis’ Total Ankle System plus patient specific instrumentation (PSI), at the American Orthopaedic Foot & Ankle Society® (AOFAS) annual meeting in Louisville, Kentucky from September 20-23, 2023.

“Enovis™ is dedicated to improving patient outcomes by introducing technologies that solve real issues in the foot and ankle industry,” stated Gary Justak, President and General Manager of Enovis™ Foot and Ankle. “Our recent acquisition of Novastep® and the Pecaplasty® Percutaneous Bunion Correction System will drive outcome improvements with an underserved patient population, and the MIS bunion surgery provides efficiency in the OR for the surgeon, while improving patient recovery times with less pain.1,2,3”

Other offerings being showcased for the first time will be Evolve34™, a bunion solution for Lapidus correction that allows surgeons to dial in deformity correction and select a hardware construct specific for the patient’s needs. Additionally, Enovis will be introducing the all new EF1 External Fixation product line, complimenting the flagship DynaNail® and DynaClip™ offerings in the hindfoot segment.

Enovis™ will also highlight products from its foot and ankle continuum of care including:

  • – MIS Bunion Correction
  • Patient Specific Instrumentation for Total Ankle Replacement
  • Walking Boot
  • A versatile stirrup design that aids in the treatment of posterior tibial tendon dysfunction (PTTD)
  • Bone Stimulation Device

AOFAS attendees have opportunities throughout the week to experience these product offerings firsthand.

  • Visit Enovis Booth #313 in the exhibit hall.
  • Register for a special Wednesday evening event, Meet us at the Winner’s Circle, September 20th from 6:30 - 9:30 p.m. Registration links and more information can be found here:
  • Educational event to hear Tyler Gonzalez, MD, MBA* present “Biomechanical Performance of Static Compression Devices Compared to NiTiNOL Compression Devices in Simulated First Metatarsophalangeal Joint Arthrodesis” on September 23 at 8:00 a.m. This presentation is part of the AOFAS Foot and Ankle Papers Session 5A: Forefoot in Ballroom A on the main level.



*Dr. Gonzalez is a paid consultant of Enovis.

CRO-2023-0229, MK-10279



About Enovis

Enovis Corporation (NYSE: ENOV) is an innovation-driven, medical technology growth company dedicated to developing clinically differentiated solutions that generate measurably better patient outcomes and transform workflows. Powered by a culture of continuous improvement, global talent and innovation, the Company’s extensive range of products, services, and integrated technologies fuels active lifestyles in orthopedics and beyond. For more information about Enovis, please visit .



  1. Lee M, Walsh J, Smith MM, Ling J, Wines A, Lam P. Hallux valgus correction comparing percutaneous chevron/Akin (PECA) and open scarf/Akin osteotomies. Foot Ankle Int. 2017;38(8):838-846. doi:10.1177/1071100717704941
  2. Maffulli N, Longo UG, Oliva F, Denaro V, Coppola C. Bosch osteotomy and scarf osteotomy for hallux valgus correction. Orthop Clin North Am. 2009;40(4):515-524. doi:10.1016/j.ocl.2009.06.003
  3. Lam P, Lee M, Xing J, Di Nallo M. Percutaneous surgery for mild to moderate hallux valgus. Foot Ankle Clin. 2016;21(3):459-477. doi:10.1016/j.fcl.2016.04.001



Media Contact:

Erica Mellema

Enovis

(269) 377-2937

Attachment



EN
18/09/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ENOVIS CORPORATION

 PRESS RELEASE

Update: Enovis Announces Fourth Quarter and Full Year 2025 Results

Update: Enovis Announces Fourth Quarter and Full Year 2025 Results Continued commercial momentum with full year 2025 sales growth of 7% on a reported basis and 6% organically Full year 2025 Reconstructive sales grew 10% Y/Y on a reported basis and 8% on an organic basis Full year 2025 Prevention & Recovery sales grew 4% Y/Y on a reported and organic basis Dallas, TX, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven medical technology growth company, today announced its financial results for the fourth quarter and full year ended December 31...

 PRESS RELEASE

Enovis Announces Fourth Quarter and Full Year 2025 Results

Enovis Announces Fourth Quarter and Full Year 2025 Results Continued commercial momentum with full year 2025 sales growth of 7% on a reported basis and 6% organically Full year 2025 Reconstructive sales grew 10% Y/Y on a reported basis and 8% on an organic basis Full year 2025 Prevention & Recovery sales grew 4% Y/Y on a reported and organic basis Dallas, TX, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven medical technology growth company, today announced its financial results for the fourth quarter and full year ended December 31, 2025. ...

 PRESS RELEASE

Enovis to Participate in the BTIG 13th Annual MedTech, Digital Health,...

Enovis to Participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference Dallas TX, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, today announced that management will participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Wednesday, February 11, 2026 in Snowbird, UT. About Enovis Enovis™ (NYSE: ENOV) is a global medical technology innovator dedicated to improving lives by developing clinically differentiated solution...

 PRESS RELEASE

Enovis to Host Fourth Quarter and Full Year 2025 Results Conference Ca...

Enovis to Host Fourth Quarter and Full Year 2025 Results Conference Call on February 26th Dallas, TX, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, announced that it will host an investor conference call and live webcast to discuss its fourth quarter and full year 2025 financial results on Thursday, February 26th, 2026 at 8:30 a.m. Eastern Time and issue an earnings press release earlier that morning. The live webcast and a presentation related to the call will be accessible from the "Investors" section of Eno...

 PRESS RELEASE

Enovis to Participate in the 44th Annual J.P. Morgan Healthcare Confer...

Enovis to Participate in the 44th Annual J.P. Morgan Healthcare Conference Dallas, TX, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, today announced that its management team will meet with investors at the 44th Annual J.P. Morgan Healthcare Conference with a presentation scheduled for Monday, January 12th, 2026, at 4:30 p.m. PST (7:30 p.m. EST). A link to the live audio webcast, as well as a copy of the accompanying presentation slides and a replay of this event, will be available on the company’s website () at...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch